Immunocore (IMCR) 10 Aug 232023 Q2 Earnings call transcript

Greetings. Welcome to the Immunocore Second Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

would Head hand of I to call time, Robertson, Clayton Investor this like the to over At Relations. Thank you.

You may begin.

Thank you.

we'll development and projected by in call, about results could of today's be statements, from forward-looking Actual certain During those materially filed statements and of today future financial the events. projections, timing release, which and activities, the those the noted risks strategy, any in and these uncertainties, XX-F Form we differ to business and as impact making our subject views including earnings recent are management's based we with morning. on SEC, issued X-Ks most including press this

undue call in today's You to disclose We'll statements on measures also these disclaims which comparable non-IFRS IFRS update are to and on measures are that. cautioned certain place reconciled today's reliance any not slides. Immunocore obligation to

will I to CEO, Dr. over Jallal. Bahija call now hand our the

Good Clay. you, morning everyone. afternoon. Welcome Thank good and

Torbay, our I'm here Mohammed CMO. today Ralph R&D; of our Dar, with Commercial; Donato, our and Brian CFO; Berman, Head David Head Di of

remarks. your closing after my will answer We questions

and During of this as another autoimmune year share quarter call, outcomes improve continue our terms delivered excellent overview with to I progress infectious in for commercially diseases. we proud of of mission deliver radically the to our with performance, that am our have first we and patients we second quarter and performance, report of cancer, pipeline. will half an disease, both to

benefit provides patients. robust $XXX That half the growth the was KIMMTRAK reflects of a to recognized execution the first commercial million. year, revenue KIMMTRAK and In that

Ralph additional for the insights execution on the QX share half year. has recently drivers Now approved in some XX over launched will second the growth in and of commercial four the KIMMTRAK countries. countries,

trial we and with on position are that cash with strong trial to thrilled at our randomized pipeline will X will update you oncology announce melanoma in Phase start through ImmTAC. today last advance durability ESMO the in David continue and patients to us presented the walk allow diseases the our first management an expense and PRAME-targeted infectious and invest to design from provide the Disciplined year. we the and we

continued patients with we to in Phase the present X combination And half year. treat the and in to monotherapy PRAME plans first have of next cohorts data

cutaneous We randomizing with KIMMTRAK. late-line are the X/X melanoma also Phase in patients trial

And our The on with application our CTA of products potential our infectious are pipeline we living new for IND on HBV and functional expansion oncology patients track candidates as IND PIWIL and continues disease investigating are HIV a with with speak. teams enrolling finally, three trials for year's end. the for ongoing as working by or people cure for

will Brian. I over now hand to

you, Thank everyone. Good morning, Bahija.

ending to report you of delivered quarter second by $XX.X primarily for details. share KIMMTRAK in today, KIMMTRAK QX, the million quarter our of Net have financial financial delighted released the grew to impressive QX Earlier SEC see our another I'm States. some million results the sales. to XX. key revenue in results. we the invite release our United $XX in from that growth On summary you'll review the Slide for and I'll highlights. of X, more our I June filings teams driven

We seven now in have with launched Italy. including countries, reimbursement

which Germany, have assumptions. our that we to pleased reached reimbursement accounting is from slightly announce improved a I'm agreement with

the September. We in publish the expect details. through take price Ralph to you Germany will launch

$XX expenses. currency loss with share-based and the of broadly flat R&D period $XX net with million $XX for SG&A Year-to-date, quarter non-cash includes QX mark-to-market expenses SG&A the approximately million. payment of of the for approximately were expense and Both million

$XX roughly in $XX million. of expense So SG&A total, cash, year-to-date net million for

Including over X the time we expense ahead, melanoma R&D announced PRAME trial increase gradually investment. new expect we Phase our to Looking as today. expand

position tax past the expense revenue, and three cash driven quarters, management. million disciplined has by U.K. of KIMMTRAK over Our credits, increase to continued $XXX

With over to that, who to I'd another KIMMTRAK Ralph, performance. review will great we'll the commercial call like the congratulate on quarter turn and the teams

and everyone. Thank you, hello, Brian,

we of approved With in in net XX Germany, XX% revenue strongest is four with Finland, Austria, quarter-over-quarter. we had $XX.X including our QX, France, potential seven this sales, million in and KIMMTRAK over up global sales. markets these year, countries markets and have represent and launched Italy, Israel. we In additional U.S., quarter-to-date estimate X/X KIMMTRAK's

the Importantly, this of fifth represents growth. quarter

please. underpinning three growth factors are Next slide, There our this quarter.

market U.S. in first-line share First, the where from we XX% in we increased in to XX% demand around our QX XX% saw growth QX.

is The second educating result on treatment are importance on the the presence clinical of remaining of healthcare around professionals our This patients driver a focus continuing that benefit. appropriately growth therapy. of of is in

Lastly, in all in Germany and nearly received Europe, first-line patients France KIMMTRAK.

a our growth have months. launches, by record including reimbursed the We to patients all driven incremental in new seen team where three KIMMTRAK transitioned Italy,

we the three-year of the two for supporting this later year expected goal. patients year, further KIMMTRAK. instrumental data Looking overall we while the continued our survival community therapy. see achieving drivers push this second the educational revenue on ahead into in from In half will expect U.S., be in significant growth KIMMTRAK's

by to several We launch Italy to also year. the expect end of additional countries grow the in continue and European

updates. move Let's to on reimbursement

its in draft in If named functionally as maintained from circumstance exempt with threshold. unique a in is would in CMS KIMMTRAK meeting language increased the shared QX, rule refund. the rule, final a the X-K, an you we KIMMTRAK for it exemption expected July this As

The outcome, pleased in In our successfully confidential Germany, be the agreed accruals with to September. until publication. completed we price higher and We're not negotiations date. remains price than published materially the which is will price

reimbursement has NICE a will to expect become, be well XXXX. and extended. unfortunately, innovative common from continue process products we It U.K., more for the the negative discussions into In decision receive funding to

to have going in ASMR an plan with and having III updated KIMMTRAK place negotiations In rating a agreement de we're confident Commission in France, the into transparence had from reimbursement XXXX. strong

our XXXX. I'm committed continued to firmly quarter patients and KIMMTRAK So up, the by year available second X,XXX remain we over our in with progress to per to making of mission sum delighted

to pass call the walk through to plans. David exciting R&D to like our now I'd you

Thank you very Ralph much,

We progress oncology going continue And make good programs. our two clinical disease pipeline. in focus I'm to today, and to infectious on

also KIMMTRAK including ESMO, cutaneous we Phase second recently going First, insights will to believe our share I'm X very XX update And original data, for and going study provide proud published PRAME. PRAME, in I'm which to patients melanoma. new how melanoma you we on develop I'm first-line to introduce from the

from that AACR KIMMTRAK We presented the data. for data earlier year. are I And these ctDNA take X at Phase there result this two first-line points

patients three-fold First, has from And informs second-line to should since benefiting move strive earlier This higher rates KIMMTRAK ctDNA clearance. patients most first-line platform lines having of where PRAME, on to the therapy. possible ctDNA we majority are in of reduction. for our based of higher to a activity that compared are second, KIMMTRAK including

at presented three uveal Also second-line years historical melanoma benefit to at we that AACR, survival controls. KIMMTRAK compared has long-term in

these following look hallmark of since to survival patients been as for therapies tale long-term a other this checkpoints. such have We IO is the

the first extend transformative with PRAME this later survival will this and share year. emergence long-term however, patients, are tumors. be that of to very and survival the platform other confidence on update three-year encouraging our Phase study benefit, increases line hope can These to to we X that The data we

combinations. of the final data been previously published recently results Most for We plus melanoma. KIMMTRAK cutaneous the to has Turning checkpoint shared.

several were would like insights to there I However, emphasize.

plus study of and increases PRAME years. two First, our control durability with this to This remarkable for partial the ongoing interest is some checkpoints. responses disease combination for over

Second, And the safety profile dosed therapy was each with alone, ImmTAC's we checkpoints. finally, have historically consistent for a monotherapy basis. confidence on providing safely with weekly PRAME combining

However, are therapy on control. backbone and can we after initial an active had of switch dosing to less when hypothesized that impacts a we combined frequent disease

study, of disease at year this to PRAME piloted doing we from to switching control. This In of are are program. for many weekly confidence their monthly similar successfully some these with provides the These most patients we applying insights with PRAME. one the KIMMTRAK maintaining

shared ovarian we a allow therapy. carcinoma patients heavily since expansions initial move lung, combination 'XX, the in Phase of into as the melanoma, that monotherapy data early us and to PRAME endometrial, care, ESMO of standards monotherapy in this and led At lines with to in X pretreated will

see registrational trial, X signals confidence in am to earlier registrational tumors first-line I some first would in And our to provide trials. that melanoma. anticipated Phase today, announce PRISM-XXX start always very We cutaneous pleased to

and XX XX roughly Here had ESMO uveal included tebentafusp with ipilimumab pembrolizumab; patients, the melanoma either cutaneous naive shared data prior year, melanoma have and patients; melanoma last which all tebentafusp. or and nivolumab prior had were of half melanoma, which we seven

Here update XX on patients. original melanoma is those an

the Even with we disease criteria strong see months in We partial X tumor RECIST did patients not a shrinkage meet partial months. some see durability, continue to responses including ranging to for durable control. response, from XX

patients these on still are therapy. Some of

pretreated the fact me is The cutaneous remarkable is that and activity monotherapy. heavily given as FXXXC being a melanoma patients administered to these are

monotherapy, combinability of our in a us and will compelling. progression-free trial Phase a in FXXXC with responses let insights and checkpoints the consider the our were to belief a coupled disease durable X first-line best platform survival. opening As clearly in This, from endpoint melanoma melanoma safety control well-tolerated the first-line profile, the primary that with work with setting

Phase increases XX In start cutaneous from our which X although additional enrolled emerging patients, original melanoma patients, the now. the to follow-up, newly less trial the the data to has conviction

design can more patient in Finally, and decision the forward. first-line how insights we frequent friendly regimen a our dosing move to platform into less solidified

the B that from FDA who PRISM-MELXXX design and study start to input the a I you with the Phase study was with for walk experts designed melanoma We through successful Type will global from us now. And had X FDA. the to meeting help and agreed design.

to country-specific control not positive of melanoma that plus FXXXC be This the arm within the Phase We control trial relatlimab. versus randomize therapy will The first nivolumab arms, are X be are we a is of nivolumab doublet. patients choice. a either plus controller metastatic of investigator includes in selection who the will aware untreated randomize previously arm HLA-XXXX checkpoint will two experimental to and or arm, cutaneous nivolumab

and and backbone. XX endpoint active two shown approach survival and are multiple endpoint is on how micrograms. clinically we were confidence the FXXXC Because well doses, include micrograms primary is dose Optimus. Project doses survival randomization XXX The FDA when to on initial reflects This to an combination an FDA's to growing consistent FXXXC The progression-free with and slide, secondary with had regimen, tolerated, the rate. that we with active in response a ImmTAC the agreed

for study drop for monotherapy intent-to-treat is in exciting X/X in one for development. analysis. time a will enrolling and recruitment analysis. no This and melanoma represents cutaneous Phase for an And is in of TCR go-forward the of their the The of after an pause lung, to is PRAME two Study which FXXXC dose there in We over included study are and us one really But largest the PRISM-MEL-XXX next expansions still endometrial The tumors, indications, continue first the per XXX four the at the XX,XXX first-line the target X patients a other importantly, at melanoma, Phase doses tumor the initial therapeutic patients is all the interim we ovarian, look the at XXX-microgram dose. opportunity for Immunocore. year.

to Per platform FDA same are will lines dose. will more progressing the discussions, provide combinations confirm will also which of standard into our the us believe help in enroll tumor and that patients we will these most Project we safety the the early some where serve allow will care XX-microgram the Optimus active. to with be with The move cohort, also types

our next track half-life with on our and for this a Finally, around our extension programs submissions for year. PRAME, franchise building are on excitement based target regulatory we PRAME-AXX

I'm to to Bahija. it back now going hand

you, Thank you, David. Thank Brian Ralph. and

is you I'm everything not see, do. can up, grateful the As team they letting for and

in and commercial this launch ahead countries could patients to additional France into the from the year, focused to half and reimbursement medical be who achieve European will expect end the momentum looking to the teams So in XXXX KIMMTRAK to we of reach benefit and of agreements on year, XXXX. maintaining second in By next globally.

first heard, have expanding with the first is commitment you as embark trial patients X XXXX. cutaneous we people our PRAME-targeted our As therapy melanoma randomize by Phase by the cancer QX with with first our aim to living - advanced on to

data as in cohorts will and potential enrolling at and continue PRAME patients of updated further also XXXX. monotherapy first will trial of the the indications, during the the X We combination half Phase we investigate and congresses share more

present In well over in this data Finally, and next intend in year. plan dose enrolling the submit three we infectious we months with trial. or in QX patients oncology, hepatocellular starting as our XX with continue to PIWIL-targeted INDs HBV multiple candidates the as we CTAs in year diseases, to the HPV ascending with next HIV, trial in carcinoma

continues Immunocore excited with to by more we ImmTACs really even execute on conclude, and To remain patients our platform. potential strategy, to our the reach

We questions. the call for will now open

you. Thank

first We Michael will now Instructions] [Operator session. from with Please Yee your with question be Jefferies. of conducting comes Our the a question. line proceed question-and-answer

and Thanks can Phase keep X data and I gave to one congrats on duration. on Phase program. the you PRAME. an progress question start morning. guess melanoma? the and David, I just a on the Good my your talk little about bit you ESMO plan update know congrats the X in to PRAME

XX%. of similar seeing had bit number ongoing you particularly rates? think in cohort the about totality that, expansion Just that the I that. I on a of Are saw of seeing data think the the just now? I talk expansion a patients? And on you were role you how played same seeing you Are response much going curves. little

what a you in looking as type, you're in that just bit a can then and to maybe you next of about PRAME? at for little you're talk you. that, lung And what ovarian the you Thank and thinking follow-up front tumor about seeing cancer did you're comment

Thank David? you, Michael.

Yes. Sure.

questions. two So

a next from view, looked we terms a this number point speak of it's update of drug very expansion, at I which again, development the the enrolling general And data, we treatment that we're in in And For won't on effect showed based PFS? durability. year. we at a which we case, benefiting? general endpoint support of share data, specifically So early, data. looked view, original the Michael, still it in, that one, Michael, ESMO. we'll But - to development ESMO percent in a the the although We're that can interested are in of What data clearly questions. from drug the was point primary ask us, population are plus two the this patients yes, promising

We Phase to that with with took and when so, X shared think that We they the sought it forward who us to clear the data. everyone move the became study. to with us agreed who FDA data KOLs and reviewed I global

saw With regard to ovarian, still to in the activity we other tumor us which That's ongoing. types, that do the expansion. triggered

well. We are very interested, endometrial of and course, in as lung

more data. the expansions still that and ongoing, on we to as are think those come So review I

Thank you.

Tyler TD your question. Our next question with Cowen. Van Please with comes from proceed the line Buren of

updates. Hi see exciting guys, morning. good the on strong quarter, KIMMTRAK Congrats and it's to all the new

Just a update. and the on PRAME durability follow-up cutaneous

response any TCR on just rate with And saw design seeing KIMMTRAK there reason why guess the So same similar and higher question durability? is KIMMTRAK? wouldn't you way, asked construct you early, I based PRAME than just durability it's initial even though How but you relative the another with to consider CDX up PRAME, when see clearly, potency, and is KIMMTRAK, confident are the you that the follow is to again, durability. are you what on

in limited and been have months. Tyler, comparison PRAME durations uveal have And KIMMTRAK response and only median direct XX has on XX we we where it's study, with duration XX-plus mostly and that's melanoma KIMMTRAK so the X monotherapy of months three XX-month, dosed the was where Phase PRAME. of we the is In because do, can the PRs the data.

But for tolerability. X. think of is I this promising PRAME in very terms Phase So Phase X, and that's is the data

The that's I right it In the for terms PRAME essentially The for gpXXX, peptide the end is we what know was is potency, of picomolar higher your CDX question. than differences end same now. is but think has the density second between TCR the molecules, that same.

Thank you.

of your proceed from BTIG. comes with question the question. Please with line Our Justin Zelin next

- question. gpXXX numbers Thanks cutaneous. in accessible for second walk here walk can for you and KIMMTRAK melanoma. taking just PRAME David, the cutaneous us for PRAME first the in you the you're Maybe for through the just obviously, - through versus third in just and market forward moving Can us versus and line

Justin. Yes,

progressed and and to ipilimumab TEBE-AM current estimate we on per X/X and to KIMMTRAK, therapy So the BRAF-targeted patients study X,XXX that be have Phase year, and anti-PD-Xs. patients X,XXX

For PRAME opportunity patients XX,XXX this, reason of part in difference than excited in That's we're the so first-line, is greater the of size. terms the year. about per

Thank you.

of Please Our with question. line Suvannavejh the next with comes Mizuho. question your Graig from proceed

Thank as thoughts Well, with PRAME. know I around on actually, and progress on you been there know me and developments that from well. focus Congrats potentially are the opportunity. on good and combining there's morning. would that I lot KIMMTRAK of melanoma just questions the A want but cutaneous KIMMTRAK I competitive landscape, to the uveal, PRAME, on

melanoma? your much. us uveal So just give can strategy overall in so you there Thanks

Yes, invite and anyone that take also. to join I'm else happy to

a benefit. had of lot a survival who benefit great KIMMTRAK So patients there's and

are and plus doing optimization. we're currently about very would We really They're excited plus the the setting. of in KIMMTRAK KIMMTRAK be It's there PRAME - the PRAME. dose combination both escalation study to first-line our drugs active idea

be once we So a data can good have that regimen, that able we'll share available and data. to have we

Thank you.

question the Our question. with with comes from next Oppenheimer. your of Please Justin line proceed Kim

Hi. you in for how is us hearing taking frame? over data HIV initial program Good we lot withdraw We're to a morning question. the potential as to the the we the patients frame term. who for exactly Maybe just should the expect pivot little time look? cut see near program. thanks just and expectation of data And bit to XX-week Can ART for what sort interest more a a

are David, - you Thanks.

I'm to take that. Yes, happy

ascending the for where then of we patients dose. a with and escalation terms the in So intra-patient treat data, at doing were XX dose weeks we multiple target

data XX well as our completed interrupt XX-week we safety we'll when for the escalations and rebound we initial will both during in. include, multiple We bispecific antiretroviral of After weeks, expect to there as data. the multiple-dose share the The course, therapy, and biomarkers run a look have of completed, will cohorts the virus.

will I weeks. within the rebound few a Historically, virus usually think

usually of four most patients within the rebound think I weeks.

We have a XX-week interruption. planned

in what HIV. has we're so, one ever for functional terms of no a care really in field. a there, mean new And looking I it's had

So we're really where excited data see this to leads us.

you. Thank

comes proceed line Guggenheim. question. Our next Michael Please of Schmidt your with from with question the

taking morning a to had my Good melanoma. PRAME and back thanks for Phase and I guys. planned question the Hi question. X study for going

KIMMTRAK it So to first the sounds by line the partially go was like decision into data. ctDNA driven

just I on wondering And something tumor was as that would first-line for the so the in other and the types whether is patients that was activity higher why ctDNA about concept, well. be case

Yes. David or Mohammed, you can?

happy start. I'm Yes. to

the data first the So based is ctDNA, on was on and also line but the based better. survival

hypotheses, second first I two that not contrast have hypothesis been might a patient's the diagnosed much immune after that the the think newly anti-PD-X. edited as fitness. perhaps have is tumors And patients have we first-line better to is in

for that's all standard So phenomena, a immunotherapies. way, the pretty by

so cutaneous larger do expect we do - haven't And well. as activity we will for expect that we mean, in but patients, first treated the the line I first-line be

Thank you.

from H.C. question. your question line proceed comes next Wainwright. Trucchio with Patrick Our Please the of with

afternoon, congrats and on morning, the good and all Thanks good progress here.

Just or question with cutaneous X/X a in second-line melanoma. Phase follow-up later the trial on KIMMTRAK

pathway study? on if With Would see might there in X what be you to that X of how portion to accelerated a inform into What randomization the completion immediately Phase accrual Phase could the I'm efficacy the potentially you following depending portion Phase Phase X from wondering portion design. implement? changes commence changes of X of the X Phase can discuss you portion,

X/X. that's Patrick, seamless lot time a we spent great of designing this question. Phase Yes, specifically a And

have board, not. have one, we'll is, KIMMTRAK have need Phase at the pembrolizumab number on pembrolizumab. KIMMTRAK-plus monotherapy, a or what we Do yes X look in we So to the we a

treatment looking can the Number of discontinue be to size treatment arm those decide may at be we larger. clear of decrease may can the So two, one arms. effect effect need is relative we trial - we the the that if control to the we'll because

you. Thank

with line Please comes the proceed next Ahu question. question your from Our Ladenburg Demir with of Thalmann.

morning. Two Congratulations for taking and my thanks our Good side. the progress on on questions.

Could What leap is that it PRAME cutaneous and by the led from on First you data melanoma. more take got by KIMMTRAK you frequent driven dosing? one X on Phase to the program? elaborate you is the only the it is or less driven

Go ahead, David?

happy I'm do Yes, to that.

the is of majority, dosing. for that the look couple about the at Number if a if in there's curves weeks. nivolumab, progression at us the occur of you - fact, Kaplan-Meier the things you look talked XX first the you Number KIMMTRAK led the progressions see X/X to we first-line one PD-Xs, that during - So of was including experience. two most

the PFS plateau trial to So dosing the weekly After Kaplan-Meier that's weeks, one that's where plan where is really because curves we and have out. last. the XX

have a look tumor the And majority by weeks. it the of didn't KIMMTRAK And other one need weeks. you think I think XX after year, of And When dosing the so, to we finally at once-monthly the a just course, regimen moves regimen. shrinkage PRAME one we also occurs in see weekly point. then, XX then we but first to data,

time to the weekly the dosing. So that's have

Thank you.

Our question line Barclays. with from Lawson of Peter comes proceed Please question. with the your next

morning. for just Peter. This the to And second a on growth for little organic question. quarter color you get KIMMTRAK? Thanks if want I [Jay] good more around is our the Hi, taking for growth - about stocking - should we volume and versus any talk here price benefits of give to one-timers U.S.? pricing you. volume the And Thank versus orders ex- be for could U.S. any thinking for growth?

Thank you for question. that

in of with the quarter-over-quarter growth. growth. January XX% the of not pure driven have that was difference U.S. se. patterns was to we X.X%. the did stocking most And per any consider growth of That see you took from beginning price demand the of the in at increase a year So We

you. Thank

the Goldman of with with [indiscernible] Nick Our Sachs. from proceed Please question. comes your next question line

of that Is of doses, ahead, that at they - seem what And Is in the to they good to an my It's - the just or looking look there. there you could could delight Thank us optically, what efficacy for apart. something PRISM then back the bar and you. questions. rationale with the dose the FDA? the you. If would see what Rajan. between? least why for was far Hi, not for idea taking and data trial thanks you come further for Nick two we just agreed there. was was wondering selection the design you've And on a give as quite just I

David?

Yes.

So were with multiple selection we tolerated Phase doses the well of X. doses, that the two and active had in

In fact, we a sevenfold had range. dose

all We XXX XX up lower And doses. we chose although micrograms. way simulation, to XXX and have the micrograms the we the originally patients based at modeling on fewer had

I XX. to reason the a dose, we that came And threshold for choose dose the choices, variability end dose. to some was the we had general, lower because think never too lowest felt or lower drug of with the was good PK, you'll two patients dose the just in a of of having up exposure. need it and explore development the in low selection XX to XX When

us on so, set that of really choice XX. And

randomized RELATIVITY-XXX going is has who PFS Opdualag. median on ranged, a regard It to, on that With who have to bar but to patients be median months. most blended less the months. some depend to X.X blended than patients nivo, median X patients I how nivolumab on will just the we're X Opdualag are I are for or probably still many some have I think months are the the PFS because recent a months going think, The efficacy, PFS perspective, from really median X.X we'll was to between think,

you. Thank

with Our comes proceed next question. Morgan the Jeff question with from of Stanley. your Hung Please line

for for 'XX data? Thanks in my taking half see expect And How to Thanks. enrollment the is AXX PRAME, what the going question. should trial? first we

do Mohamed, to want that? you Great. take

Sure.

earlier, footing to X we Phase As we said a from moved had Phase a footing. X have

So of priority up as the open cohorts to and to expansion our accrue combination. sites care well additional we continue to standard as continue multiple

So we've we continues to to half that all matures And said, plan to according of year? next go plan. data in share the the it first of as as

you. Thank

Gil proceed Needham question. from Blum with your the question of & Our comes Please next Co. line with

morning, Good thanks and taking our question. everyone, for

be the at it'd data agent the way So suggested and be PRAME previously to would what this you. ton play activity, post but other KIMMTRAK agent of the this hypothetical is Thank bit of happens When a kind you a KIMMTRAK see of interesting the PRAME melanoma. you around? it there but did expected and cutaneous in point, a what was between

Yes.

was So the part see mel after and stabilization KIMMTRAK there. in we - saw the uveal response in that RECIST really although PRAME cutaneous so we was remarkable, didn't disease

Now and disease stabilization we why We like first saw don't speculate, responses can we was it We but that. don't in RECIST partial line? know not know.

excited it in are PRAME makes our really It we there. study you combinations. think to I a have to we KIMMTRAK multiple because plus uveal sense do lot study works of understand when how platform melanoma to initially experience KIMMTRAK

But I think clearly, cutaneous melanoma would be step. the next

PRAME within the to we the the ways and more Gil. T is be One broadly expressed, could might gpXXX cells HLA on that co-express two And for cell could more you it, also to think peptide tumor. cells kill. are are about for there cell because there both both, I think think target targets

hypotheses. active think are I those both of So

There any for would back Thank closing like floor the now questions Bahija comments. time, Jallal this turn I to to no are at you. further over

Thank you, thank Yes. made. I taking to that and the everyone operator. time we've just want listening to for the progress today

So much. thank you very

This appreciate does your you. We conclude teleconference. Thank participation. today's

this time. of at the lines your your disconnect Enjoy may rest You day.